Company: CSTL
Filing Date: 2025-03-28
Form Type: PRE 14A
Source: 0001447362-25-000050
Chunk: 5

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-03-28
Form: PRE 14A
Chunk 5
---
 CEO and Director of Amylin Pharmaceuticals, Inc.                                                                                                                                                                
 •Serves on the board of directors of numerous privately held companies.                                                                                                                                                                          
 •Holds a B.S. degree in pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.                                                                       |     | •Commercial Execution                             
 •Life Science Industry Experience                 
 •Financial Analysis & Control Experience          
 •R&D Scientific Leadership                        
 •Regulatory/Lab Services Reimbursement            |
| Rodney Cotton                    
 Comp. Committee                  |     | •Previously served as Senior Vice President, Chief of Staff and Head of Strategy and Transformation at Roche Diagnostics. Also served as Interim Head of Communications and Senior Vice President, Commercial Operations/West Zone.              
 •Serves on the board of directors of numerous privately held companies.                                                                                                                                                                          
 •Holds a B.A. in Biological Sciences & Technology from the University of California, Santa Barbara, an M.S. in Strategic Management from the University of Southern California, and an MBA from the California State University Dominguez Hills. |     | •Commercial Execution                             
 •Life Science Industry Experience                 
 •Financial Analysis & Control Experience          
 •Digital Health                                   
 •Health System Experience                         
 •Regulatory/Lab Services Reimbursement            
 •Diversity of Skills, Background, and Perspective |

#### 6Castle Biosciences 2024 Proxy Statement

#### Proxy Summary

### GOVERNANCE HIGHLIGHTS
Our Board is committed to building long-term stockholder value and maintaining sound corporate governance practices. Based on discussions with stockholders and corporate governance best practices, our Board adopted stock ownership guidelines and other governance policies in 2023 to align our corporate governance practices with market practices and investor expectations:

• Director Time Commitment Policy. Our Nominating and Corporate Governance Committee has ongoing discussions on the topic of director time commitments and review the policies of peers and other public companies, as well as various institutional policies. Further, as part of our stockholder outreach, we discussed this topic with many of our investors. Based on this information, and taking into consideration stockholder feedback, our Board adopted a policy in 2023 (our “Director Time Commitment Policy”), as outlined below.

◦ A director who is not also an “officer” (each, a “Section 16 officer” (as defined in Rule 16a-1(f) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), may serve on a total